Intellia Therapeutics (NASDAQ:NTLA) Trading Up 10.1% - What's Next?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report)'s stock price traded up 10.1% during mid-day trading on Monday . The company traded as high as $7.83 and last traded at $7.96. 607,328 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 2,343,039 shares. The stock had previously closed at $7.23.

Analyst Upgrades and Downgrades

NTLA has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Wedbush restated a "neutral" rating and set a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. BMO Capital Markets decreased their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a report on Friday, January 10th. Oppenheimer lowered their target price on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Finally, StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $36.68.

Intellia Therapeutics Price Performance

The firm has a fifty day simple moving average of $8.66 and a two-hundred day simple moving average of $11.85. The firm has a market cap of $860.23 million, a price-to-earnings ratio of -1.53 and a beta of 2.23.

Institutional Trading of Intellia Therapeutics

Several institutional investors have recently modified their holdings of NTLA. GF Fund Management CO. LTD. acquired a new stake in shares of Intellia Therapeutics in the 4th quarter worth $25,000. Sterling Capital Management LLC increased its stake in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new stake in Intellia Therapeutics during the 4th quarter worth approximately $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $43,000. Finally, Jones Financial Companies Lllp raised its holdings in Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after acquiring an additional 2,280 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.